WaveMan
WaveMan · Company
CDXS · Codexis, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CDXS Codexis (CDXS) Insider Trading, Ownership & Congress Trades

Materials · Industrial organic chemicals · CIK 0001200375
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
88
13F, latest reported quarter

What the filings say about CDXS

Insiders, 180 days
-$23.4K net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$17.2K
2 notices

Codexis insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CODEXIS, INC. insiders sold a net $23.4K of stock across 124 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
MOORE ALISON
President and CEO
SELL
2026-10-14 SECtraded 2026-10-12
6,335
$8.6K
-4.4%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Feb 6, 2026.
  • The trade is 2.6% of the 244,171 shares held after it.
  • 1 other insider sold within 30 days.
  • 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO MOORE ALISON sold about $8.6K of CDXS on Oct 12, 2026; 1 other insider sold within 30 days and 88 funds added in the latest 13F quarter.
Erbez Georgia
See Remarks
SELL
2026-10-14 SECtraded 2026-10-12
6,335
$8.6K
-4.4%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Feb 6, 2026.
  • The trade is 10.5% of the 60,475 shares held after it.
  • 1 other insider sold within 30 days.
  • 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Erbez Georgia sold about $8.6K of CDXS on Oct 12, 2026; 1 other insider sold within 30 days and 88 funds added in the latest 13F quarter.
De Vre Raymond
Director
SELL
2026-06-11 SEC
2,605
$6.2K
-45.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Nov 11, 2025.
  • The trade is 3.1% of the 84,811 shares held after it.
  • No other insider sold within 30 days.
  • 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director De Vre Raymond sold about $6.2K of CDXS on Jun 11, 2026; 88 funds added in the latest 13F quarter.
Lutz Stefan
Chief Scientific Officer
SELL
2026-02-25 SECtraded 2026-02-24
5,862
$6.6K
+21.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Feb 6, 2026.
  • The trade is 4.5% of the 130,421 shares held after it.
  • 2 other insiders sold within 30 days.
  • 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Lutz Stefan sold about $6.6K of CDXS on Feb 24, 2026; 2 other insiders sold within 30 days and 88 funds added in the latest 13F quarter.
Lutz Stefan
Chief Scientific Officer
SELL
2026-02-09 SECtraded 2026-02-06
2,492
$3.3K
+4.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jan 7, 2026.
  • The trade is 1.8% of the 136,283 shares held after it.
  • 2 other insiders sold within 30 days.
  • 88 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Lutz Stefan sold about $3.3K of CDXS on Feb 6, 2026; 2 other insiders sold within 30 days and 88 funds added in the latest 13F quarter.
124 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 119 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$23.4K over 180 days
-$17.2K over 90 days
more than 61% of Materials
Congress
no House purchase disclosed in the last 12 months
Funds
88 funds bought in last quarter
below 60% of Materials
Revenue
+18.6% year over year
more than 85% of Materials
Margin
-62.5% net margin
below 88% of Materials
Buybacks
no share repurchases reported
Short interest
5.9% of the float short (float per yahoo 2026-10-26) · 5.0 days to cover · settled 2026-09-30
more than 59% of Materials
What changed in the last 30 days
Oct 14See Remarks Erbez Georgia sold $8.6K (Oct 12)
Oct 14President and CEO MOORE ALISON sold $8.6K (Oct 12)
Oct 13Officer Erbez Georgia filed to sell $8.6K by Oct 12 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 13Officer MOORE ALISON filed to sell $8.6K by Oct 12 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch CDXS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-49.8%12M
-62%-38%-14%+10%2025-102025-122026-022026-042026-062026-082026-10 2025-11-12 · Opaleye Management Inc. sold $1.7M2025-11-11 · Opaleye Management Inc. sold $963.0K2025-11-07 · Opaleye Management Inc. sold $504.4K2025-12-01 · Opaleye Management Inc. sold $409.1K2025-11-10 · Opaleye Management Inc. sold $354.6K2025-11-12 · Opaleye Management Inc. sold $323.4K2025-11-26 · Opaleye Management Inc. sold $258.1K2025-11-28 · Opaleye Management Inc. sold $183.8K2025-11-12 · Opaleye Management Inc. sold $53.3K2025-11-11 · Opaleye Management Inc. sold $23.8K2025-11-07 · Opaleye Management Inc. sold $17.0K2025-12-01 · Opaleye Management Inc. sold $14.3K2025-11-21 · WOLF DENNIS P sold $14.0K2025-11-26 · Opaleye Management Inc. sold $8.7K2026-10-12 · MOORE ALISON sold $8.6K2026-10-12 · Erbez Georgia sold $8.6K2026-01-07 · Lutz Stefan sold $8.0K2026-02-24 · Lutz Stefan sold $6.6K2026-06-11 · De Vre Raymond sold $6.2K2025-11-10 · Opaleye Management Inc. sold $5.7K2026-02-06 · Erbez Georgia sold $5.0K2026-02-06 · MOORE ALISON sold $5.0K2025-11-28 · Opaleye Management Inc. sold $4.4K2026-02-06 · Lutz Stefan sold $3.3K2025-11-11 · De Vre Raymond sold $2.5K2026-10-13 · Erbez Georgia filed to sell $8.6K2026-10-13 · MOORE ALISON filed to sell $8.6K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CDXS: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
7,284,352 sh
$16.5M
Nantahala Capital Management, LLC
7,247,226 sh
$16.4M
Opaleye Management Inc.
6,785,000 sh
$15.3M
Aberdeen Group plc
6,769,954 sh
$15.3M
MILLENNIUM MANAGEMENT LLC
5,549,139 sh
$12.5M

Congress trades in CDXS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CDXS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Erbez Georgia
Filed 2026-10-13
$8.6K
MOORE ALISON
Filed 2026-10-13
$8.6K

CDXS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Jacob Discovery Fund
$429.0K position · as of 2026-05-31
2.7%
Invesco NASDAQ Future Gen 200 ETF
$211.0K position · as of 2026-05-31
1.1%
Putnam Small Cap Value Fund
$1.4M position · as of 2026-05-31
0.5%
Putnam VT Small Cap Value Fund
$419.7K position · as of 2026-06-30
0.3%
Columbia Variable Portfolio - Small Cap Value Discovery Fund
$1.1M position · as of 2026-06-30
0.2%
Ultra-Small Company Market Fund
$264.4K position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Stephen Dilly
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$3.5M
$6.2M
$1.3M
+2%
n/a
2023
$3.1M
$1.2M
$1.9M
-35%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $23.4K sold by insiders over 180 days, 88 funds added last quarter, $17.2K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
JELDLEGHWMSAVYSXTENTGREXGEVOCMTKOPNKEBNET

CDXS financials

Revenue growth
+18.6%
XBRL, annual
Net margin
-62.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$77.7M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-39.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$12.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
1.24x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-0.25x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-69.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-23.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-25.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$156.1M
market value at close 2026-10-26 on 2026-08-06 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-8.6%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$70.4M$59.3M$70.1M$138.6M
Operating income-$41.7M-$58.5M-$68.1M-$34.9M
Net income-$44.0M-$65.3M-$76.2M-$33.6M
EPS (diluted)-0.50-0.89-1.12-0.51
Operating cash flow-$19.4M-$49.4M-$52.6M$11.3M
Cash$50.8M$19.3M$65.1M$114.0M
Long-term debt$40.1M$28.9M$0n/a
SEC XBRL, fiscal years, as known on 2026-10-28

CDXS Stock Sonar score 6/7 axes

Find similar shapesCompare

CDXS ranks highest on growth (85th percentile) and risk and compliance (63rd), and lowest on profitability (12th), among Materials peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
12
Inputs
  • Return on equity-69.4% · 8 pct, sector of 100
  • Return on assets-23.8% · 17 pct, sector of 120
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-25.2% · 12 pct, sector of 96
Financial health
18
Inputs
  • Debt to equity1.24x · 20 pct, sector of 104
  • Cash flow to debt-0.25x · 16 pct, sector of 103
Growth
85
Inputs
  • Revenue growth, YoY+18.6% · 85 pct, sector of 128
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
30
Inputs
  • Net Form 4 buying (codes P and S), 180d-$23K · 61 pct, sector of 80
  • Insider buyers, 180d0 · 0 pct, sector of 80
Institutional and government
40
Inputs
  • Funds adding, latest quarter88 · 40 pct, sector of 118
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
63
Inputs
  • Short interest, % of float+5.9% · 39 pct, sector of 143
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5y0.00 per $1B · 100 pct, sector of 103
  • New text in Risk Factors, latest 10-K+11.3% · 50 pct, sector of 111
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CDXS filings, in plain words

Are Codexis insiders buying or selling CDXS?

In the 180 days to 2026-10-28, Codexis insiders were net sellers, a net $23.4K across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of CDXS?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $17.2K of stock; the latest, by Erbez Georgia, was filed 2026-10-13.

Read the full summary

In the 180 days to 2026-10-28, Codexis insiders were net sellers of CDXS, a net $23.4K across purchases and sales reported on Form 4 by 3 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $17.2K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies